A listing of Type 2 Diabetes Mellitus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
The AMPLIFY EP Registry is an observational, prospective, multi-center, non-randomized registry designed to obtain real world clinical experience with the TactiFlex Catheter Ablation system in the treatment of Atrial Fibrillation. Patient assessments will occur at pre- procedure and procedure, and 1 year post ablation.
The purpose of the IMPaCT Transitions program is to help low-income general medicine patients who have been cared for at the Hospital of the University of Pennsylvania or Presbyterian Hospital with the transition from hospital to a primary care clinic. The purpose of IMPaCT Home is to help low-SES patients …
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who …
Study is enrolling participants with IgA nephropathy to study safety and effectiveness of sparsentan in combination with SGLT2 inhibition. Participants are enrolled for 28 weeks and if taking any ACEI or ARB therapies, must discontinue prior to Day 1 visit.
This study will analyze the potential lung protective effect of mild therapeutic hypothermia (TH), similar to that used for cardiac arrest, in ICU patients with acute respiratory distress syndrome (ARDS).
The purpose of this study is to study how a new investigational drug called lucerastat works in research subjects. Taking part in a research study is different from getting regular medical care. The aim of regular care is to improve your health. The aim of a research study is to …
This study seeks enroll 390 adult males and females with Severe Hypertriglyceridemia and with fasting TG 500 mg/dL (5.65 mmol/L) that are over the age of 18. The primary objective is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting TG from Baseline.
This study aims to identify how useful polygenic and integrated risk is in both helping doctors to treat and manage their patients, and identifying people at risk of developing coronary artery disease. Targeted population is previously genotyped individuals in the PMBB. We will calculate an integrated risk score for coronary …
To assess the effect of nintedanib on preserving L-PF measured symptom levels (cough, dyspnea, energy), impacts of disease, and quality of life in patients with MA-ILD who are also receiving SOC treatment.
To assess safety and tolerability, including dose-limiting toxicities (DLTs), maximum tolerated dose (MTD), or maximum administered dose (MAD; if no MTD is defined) of IMGN151 when administered intravenously To determine recommended Phase 2 dose (RP2D) for IMGN151 To characterize the pharmacokinetics (PK) and immunogenicity of IMGN151 -To assess ORR for …